Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31286711 | 0.90 | SCN9A (0.44) | SMN1; SMN2TLR8EPHX2 | |
| SCHEMBL20572924 | 0.89 | USP2 (0.43) | USP2SMN1; SMN2TLR8EPHX2ACKR3 | |
| SCHEMBL20211851 | 0.86 | TLR8 (0.43) | USP2SMN1; SMN2TLR8ACKR3CHRM2 | |
| SCHEMBL30097282 | 0.86 | CYP2D6 (0.43) | USP2SMN1; SMN2ALDH1A1EPHX2 | |
| SCHEMBL20211861 | 0.85 | USP2 (0.45) | USP2SMN1; SMN2TLR8EPHX2ACKR3 | |
| SCHEMBL21068826 | 0.84 | TLR8 (0.46) | USP2SMN1; SMN2TLR8ALDH1A1EPHX2 | |
| SCHEMBL22262696 | 0.84 | USP2 (0.44) | USP2SMN1; SMN2TLR8ALDH1A1EPHX2 | |
| SCHEMBL6661328 | 0.84 | USP2 (0.44) | USP2SMN1; SMN2TLR8ALDH1A1EPHX2 | |
| SCHEMBL15352136 | 0.84 | USP2 (0.44) | USP2SMN1; SMN2TLR8ALDH1A1EPHX2 | |
| SCHEMBL7605519 | 0.84 | TLR8 (0.46) | USP2SMN1; SMN2TLR8EPHX2ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0927173-B1 | SUBSTITUTED [2-(1-PIPERAZINYL)ETHOXY]METHYL | UCB SA (BE) | 2002-06-12 | — | — | EP | claimed |
| CN-1072661-C | Novel substituted [2-(1-piperazinyl) ethoxy] methyl | UCB SA (BE) | 2001-10-10 | — | — | CN | claimed |
| US-6140501-A | CHEMICAL INTERMEDIATES | UCB, S.A. (BE) | 2000-10-31 | — | — | US | claimed |
| CN-1215395-A | Novel substituted [2-(1-piperazinyl) ethoxy] methyl | UCB SA (BE) | 1999-04-28 | — | — | CN | claimed |
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025022093-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2025-01-30 | — | — | WO | disclosed |
| CN-1072661-C | Novel substituted [2-(1-piperazinyl) ethoxy] methyl | UCB SA (BE) | 2001-10-10 | — | — | CN | disclosed |
| US-6255487-B1 | PREPARING 2-(2-(4-((4-CHLOROPHENYL)PHENYLMETHYL)-1-PIPER-AZINYL)ETHOXY)ACETIC ACID VIA REACTING SUBSTITUTED (2-((1-PIPERAZINYL)ETHOXY)METHYL COMPOUND WITH A DIPHENYLMETHYL HALIDE, THEN HYDROLYZING IN ALCOHOLIC MEDIUM WITH ACID/BASE | UCB, S.A. (BE) | 2001-07-03 | — | — | US | disclosed |
| US-6140501-A | CHEMICAL INTERMEDIATES | UCB, S.A. (BE) | 2000-10-31 | — | — | US | disclosed |
| CN-1215395-A | Novel substituted [2-(1-piperazinyl) ethoxy] methyl | UCB SA (BE) | 1999-04-28 | — | — | CN | disclosed |